US2014179925A1PendingUtilityA1
Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
Est. expirySep 4, 2029(~3.1 yrs left)· nominal 20-yr term from priority
C07D 405/06C07D 401/06C07D 215/14C07D 307/52C07D 213/50C07D 295/192C07D 409/06C07D 333/22
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein are methods of treating a patient suffering from a cognitive disorder using compounds of Formulas 1 and 2 wherein the variables have the meaning disclosed in the specification
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
where R 1 is H or alkyl of 1 to 6 carbons,
R 2 is H, alkyl of 1 to 6 carbons or the R 1 and R 2 groups together with the nitrogen form a saturated or unsaturated 4, 5, 6 or 7 membered ring that optionally includes one or two heteroatoms independently selected from N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen groups, cyano groups, or with one or two alkyl groups having 1 to 6 carbons, or one or two carbons of said rings being attached to an oxygen to form keto groups and said 4, 5, 6 or 7 membered ring optionally being condensed with an aromatic or non-aromatic 5 or 6 membered ring that optionally includes 1 or heteroatoms selected from N, O and S;
R 3 is independently selected from H, alkyl of 1 to 20 carbons, cycloalkyl of 3 to 6 carbons, aryl or heteroaryl, aryl-alkyl where the alkyl moiety has 1 to 4 carbons, aryl-(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, heteroaryl-alkyl where the alkyl moiety has 1 to 4 carbons, or hetero-(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, or R 3 is CO—R 7 , SO 2 R 7 or CO—O—R 7 where R 7 is H, alkyl of 1 to 1 to 20 carbons, alkyl of 1 to 20 carbons substituted with and NH 2 group or with an NH—COalkyl group where the alkyl group has one to 6 carbons, aryl or heteroaryl, aryl-alkyl where the alkyl moiety has 1 to 4 carbons or heteroaryl-alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons;
R 4 is H, alkyl of 1 to 6 carbons or CO—R 8 where R 8 is alkyl of 1 to 6 carbons;
the wavy lines represent bonds connected to carbons having R or S configuration;
the dashed lines represent a bond or absence of a bond with the proviso that the ring containing the dashed lines is aromatic;
m, n and q are integers independently selected from 0, 1, 2 or 3 with the proviso that the sum of m, n and q is 2 or 3;
s is zero (0) or when X is N then s is zero (0) or 1;
W, X and Y independently represent a CH, CR 5 , CR 6 or a heteroatom selected independently of N, O and S, and
R 5 and R 6 are independently selected from H, halogen, alkyl of 1 to 6 carbons, halogen substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, phenyl, or
R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S;
said carbocyclic or heterocyclic ring jointly formed by R 5 and R 6 being optionally substituted with 1 to 6 R 9 groups where R 9 is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons or a pharmaceutically acceptable salt of said compound with the proviso that Formula 1 does not cover compounds where R 4 is H, R 1 and R 2 jointly with the nitrogen form a pyrrolidino or morpholino ring, the sum of m, n and q is 3, and where none of W, X and Y represent a heteroatom with the further proviso that the formula does not cover the compounds of the formula below
2 . The use of claim 1 , wherein the sum of the integers m, n and q is 3.
3 . The use of claim 2 , wherein one of the W, X and Y groups is N.
4 . The use of claim 3 , wherein R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring.
5 . The use of claim 2 , wherein none of the W, X and Y groups is a heteroatom.
6 . The use of claim 5 wherein R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring.
7 . The use of claim 1 , wherein the sum of the integers m, n and q is 2 and at least one of W, X and Y is a heteroatom.
8 . The use of claim 7 , wherein only one of W, X and Y represents a heteroatom.
9 . The use of claim 7 , wherein two of the W, X and Y groups each represent an independently selected heteroatom.
10 . The use of claim 1 , wherein R 4 is H.
11 . The use of claim 10 , wherein both R 3 groups are H.
12 . The use of claim 10 , wherein one R 3 group is H and the other R 3 group is CO—R 7 or alkyl of 1 to 20 carbons.
13 . The use of claim 10 , wherein R 3 is independently selected from H and alkyl of 1 to 10 carbons.
14 . The use of claim 1 , wherein R 4 is CO—R 8 .
15 . The use of claim 1 , wherein R 1 and R 2 together with the nitrogen form a 4, 5, 6 or 7 membered ring.
16 . The use of claim 15 , wherein R 1 and R 2 together with the nitrogen form a 5 membered ring.
17 . The use of claim 15 , wherein R 1 and R 2 together with the nitrogen form a 6 membered ring.
18 . The use of claim 1 , wherein both R 5 and R 6 are hydrogen.
19 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
where R 1 is H or alkyl of 1 to 6 carbons,
R 2 is H, alkyl of 1 to 6 carbons or the R 1 and R 2 groups together with the nitrogen form a saturated or unsaturated 4, 5, 6 or 7 membered ring that optionally includes one or two heteroatoms independently selected from N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen groups, cyano groups or with one or two alkyl groups having 1 to 6 carbons;
R 3 is H, CO—R 7 or CO—O—R 7 where R 7 is H, alkyl of 1 to 1 to 20 carbons, cycloalkyl of 3 to 6 carbons, aryl or heteroaryl, aryl-alkyl, aryl(hydroxy)alkyl, heteroaryl-alkyl or heteroalkyl(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons;
R 4 is H, alkyl of 1 to 6 carbons, or CO—R 8 where R 8 is alkyl of 1 to 6 carbons,
R 5 and R 6 are independently selected from H, halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, or
R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S;
said carbocyclic or heterocyclic ring jointly formed by R 5 and R 6 being optionally substituted with 1 to 6 R 9 groups where R 9 is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, and
the wavy lines represent bonds of the alpha or beta configuration, or any pharmaceutically acceptable salt of said compound.
20 . The use of claim 19 , wherein R 4 is H.
21 . The use of claim 19 , wherein both R 3 groups are H.
22 . The use of claim 19 , wherein both R 5 and R 6 are hydrogen.
23 . The use of claim 19 , wherein the compound has the formula
or a pharmaceutically acceptable salt of said compound.
24 . The use of claim 23 , wherein R 4 is H.
25 . The use of claim 23 , wherein both R 3 groups are H.
26 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
where R 1 is H or alkyl of 1 to 6 carbons,
R 2 is alkyl of 1 to 6 carbons or the R 1 and R 2 groups together with the nitrogen form a saturated or unsaturated 4, 5, 6 or 7 membered ring that optionally includes one or two heteroatoms independently selected from N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen groups, cyano groups, or with one or two alkyl groups having 1 to 6 carbons,
R 3 is H, CO—R 7 or CO—O—R 7 where R 7 is H, alkyl of 1 to 1 to 20 carbons, aryl or heteroaryl, cycloalkyl of 3 to 6 carbons, aryl-alkyl aryl(hydroxy)alkyl, heteroaryl-alkyl or heteroaryl(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons;
R 4 is H, alkyl of 1 to 6 carbons, or CO—R 8 where R 8 is alkyl of 1 to 6 carbons;
R 5 and R 6 are independently selected from H, halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, thioxy of 1 to 3 carbons and phenyl, or
R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S;
said carbocyclic or heterocyclic ring jointly formed by R 5 and R 6 being optionally substituted with 1 to 6 R 9 groups where R 9 is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, and the wavy lines represent bonds connected to carbons having R or S of configuration, with the proviso that the claim does not cover compounds where R 4 is H, R 1 and R 2 jointly with the nitrogen form a pyrrolidino or morpholino ring, or any pharmaceutically acceptable salt of said compound.
27 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
where X is O or S;
R 1 is H or alkyl of 1 to 6 carbons,
R 2 is H, alkyl of 1 to 6 carbons or the R 1 and R 2 groups together with the nitrogen form a saturated or unsaturated 5 or 6 membered ring that optionally includes one or two heteroatoms independently selected from N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen groups or cyano groups with one or two alkyl groups having 1 to 6 carbons,
R 3 is H, CO—R 7 or CO—O—R 7 where R 7 is H, alkyl of 1 to 1 to 20 carbons, aryl or heteroaryl, aryl-alkyl, aryl(hydroxy)alkyl, heteroaryl-alkyl or heteroaryl(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons;
R 4 is H, alkyl of 1 to 6 carbons, or CO—R 8 where R 8 is alkyl of 1 to 6 carbons;
R 5 and R 6 are independently selected from H, halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, or
R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S;
said carbocyclic or heterocyclic ring jointly formed by R 5 and R 6 being optionally substituted with 1 to 6 R 9 groups where R 9 is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, and
the wavy lines represent bonds connected to carbons having R or S configuration, or any pharmaceutically acceptable salt of said compound
with the further proviso that the claim does not cover the compound shown below
28 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
where R 1 is H or alkyl of 1 to 6 carbons,
R 2 is H, alkyl of 1 to 6 carbons or the R 1 and R 2 groups together with the nitrogen form a saturated or unsaturated 4, 5, 6 or 7 membered ring that optionally includes one or two heteroatoms independently selected from N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen or cyano groups or with one or two alkyl groups having 1 to 6 carbons, or one or two carbons of said rings being attached to an oxygen to form keto groups and said 4, 5, 6 or 7 membered ring optionally being condensed with an aromatic or non-aromatic 5 or 6 membered ring that optionally includes 1 or heteroatoms selected from N, O and S;
R 3 is independently selected from H, alkyl of 1 to 20 carbons, cycloalkyl of 3 to 6 carbons, aryl or heteroaryl, aryl-alkyl where the alkyl moiety has 1 to 4 carbons, aryl-(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, heteroaryl-alkyl where the alkyl moiety has 1 to 4 carbons or hetero-(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, or R 3 is CO—R 7 , SO 2 R 7 or CO—O—R 7 where R 7 is H, alkyl of 1 to 1 to 20 carbons, alkyl of 1 to 20 carbons substituted with and NH 2 group or with an NH—COalkyl group where the alkyl group has one to 6 carbons aryl or heteroaryl, aryl-alkyl where the alkyl moiety has 1 to 4 carbons or heteroaryl-alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons;
the wavy lines represent bonds connected to carbons having R or S configuration;
the dashed lines represent a bond or absence of a bond with the proviso that the ring containing the dashed lines is aromatic;
R 9 and R 10 are one of the combinations selected from the group consisting of (1) R 9 is NOR 11 and R 10 does not exist, (2) R 9 is OR 11 and R 10 is alkyl of 1 to 6 carbons, (3) when the dashed lines between carbons 2 and 3 of the propionic acid moiety represent a bond then R 9 is H or alkyl of 1 to 6 carbons and R 10 does not exist;
R 11 is H, alkyl of 1 to 6 carbons or CO—R 12 where R 12 is alkyl of 1 to 6 carbons;
m, n and q are integers independently selected from 0, 1, 2 or 3 with the proviso that the sum of m, n and q is 2 or 3;
is zero (0) or when X is N then s is zero (0) or 1;
W, X and Y independently represent a CH, CR 5 , CR 6 or a heteroatom selected independently of N, O and S, and
R 5 and R 6 are independently selected from H, halogen, alkyl of 1 to 6 carbons, halogen substituted alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons, phenyl, or
R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S;
said carbocyclic or heterocyclic ring jointly formed by R 5 and R 6 being optionally substituted with 1 to 6 R 12 groups where R 12 is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons or a pharmaceutically acceptable salt of said compound.
29 . The use of claim 28 , wherein the sum of the integers m, n and q is 3.
30 . The use of claim 28 , wherein one of the W, X and Y groups is N.
31 . The use of claim 28 , wherein the R 1 and R 2 groups together with the nitrogen form a 5-membered ring.
32 . The use of claim 28 , wherein R 9 is NOR 11 and R 10 does not exist.
33 . The use of claim 28 , wherein R 9 is methyl and R 10 is OR 11 .
34 . The use of claim 28 , wherein the dashed line between carbons 2 and 3 represents a bond.
35 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
36 . The use of claim 35 , wherein the compound is (2S,3S)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(thiophen-3-yl)propan-1-one.
37 . The use of claim 35 , wherein the compound is (2S,3R)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(thiophen-3-yl)propan-1-one.
38 . The use of claim 35 , wherein the compound is (2R,3S)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(thiophen-3-yl)propan-1-one.
39 . The use of claim 35 , wherein the compound is (2R,3R)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(thiophen-3-yl)propan-1-one.
40 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
41 . The use of claim 40 , wherein the compound is (2S,3S)-2-amino-3-hydroxy-3-(pyridin-3-yl)-1-(pyrrolidin-1-yl)propan-1-one.
42 . The use of claim 40 , wherein the compound is (2S,3R)-2-amino-3-hydroxy-3-(pyridin-3-yl)-1-(pyrrolidin-1-yl)propan-1-one.
43 . The use of claim 40 , wherein the compound is (2R,3S)-2-amino-3-hydroxy-3-(pyridin-3-yl)-1-(pyrrolidin-1-yl)propan-1-one.
44 . The use of claim 40 , wherein the compound is (2R,3R)-2-amino-3-hydroxy-3-(pyridin-3-yl)-1-(pyrrolidin-1-yl)propan-1-one.
45 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
46 . The use of claim 45 , wherein the compound is (2S,3S)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one.
47 . The use of claim 45 , wherein the compound is (2S,3R)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one.
48 . The use of claim 45 , wherein the compound is (2R,3S)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one.
49 . The use of claim 45 , wherein the compound is (2R,3R)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one.
50 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
51 . The use of claim 50 , wherein the compound is (2S,3S)-2-amino-3-hydroxy-1-(piperidin-1-yl)-3-(pyridin-4-yl)propan-1-one.
52 . The use of claim 50 , wherein the compound is (2S,3R)-2-amino-3-hydroxy-1-(piperidin-1-yl)-3-(pyridin-4-yl)propan-1-one.
53 . The use of claim 50 , wherein the compound is (2R,3S)-2-amino-3-hydroxy-1-(piperidin-1-yl)-3-(pyridin-4-yl)propan-1-one.
54 . The use of claim 50 , wherein the compound is (2R,3R)-2-amino-3-hydroxy-1-(piperidin-1-yl)-3-(pyridin-4-yl)propan-1-one.
55 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure
56 . The use of claim 55 , wherein the compound is (2S,3S)-2-amino-3-(furan-3-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
57 . The use of claim 55 , wherein the compound is (2S,3R)-2-amino-3-(furan-3-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
58 . The use of claim 55 , wherein the compound is (2R,3S)-2-amino-3-(furan-3-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
59 . The use of claim 55 , wherein the compound is (2R,3R)-2-amino-3-(furan-3-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
60 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure
61 . The use of claim 60 , wherein the compound is (2S,3S)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(quinolin-4-yl)propan-1-one.
62 . The use of claim 60 , wherein the compound is (2S,3R)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(quinolin-4-yl)propan-1-one.
63 . The use of claim 60 , wherein the compound is (2R,3S)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(quinolin-4-yl)propan-1-one.
64 . The use of claim 60 , wherein the compound is (2R,3R)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-(quinolin-4-yl)propan-1-one.
65 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
66 . The use of claim 65 , wherein the compound is (2S,3S)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-p-tolylpropan-1-one.
67 . The use of claim 65 , wherein the compound is (2S,3R)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-p-tolylpropan-1-one.
68 . The use of claim 65 , wherein the compound is (2R,3S)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-p-tolylpropan-1-one.
69 . The use of claim 65 , wherein the compound is (2R,3R)-2-amino-3-hydroxy-1-(pyrrolidin-1-yl)-3-p-tolylpropan-1-one.
70 . The use of a compound in the manufacture of a medicament for treating a cognitive disorder, wherein the compound has the following structure:
71 . The use of claim 70 , wherein the compound is (2S,3S)-2-amino-3-(biphenyl-4-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
72 . The use of claim 70 , wherein the compound is (2S,3R)-2-amino-3-(biphenyl-4-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
73 . The use of claim 70 , wherein the compound is (2R,3S)-2-amino-3-(biphenyl-4-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
74 . The use of claim 70 , wherein the compound is (2R,3R)-2-amino-3-(biphenyl-4-yl)-3-hydroxy-1-(pyrrolidin-1-yl)propan-1-one.
75 . The use according to any of the preceding claims, wherein the cognitive disorder is selected from the group consisting of an agnosia, an amnesia, an aphasia, an apraxia, a delirium, a dementia, and a learning disorder.
76 . The use according to claim 75 , wherein the cognitive disorder is selected from the group consisting of AIDS dementia complex, Binswanger's disease, dementia with Lewy Bodies, frontotemporal dementia, mild cognitive impairment, multi-infarct dementia, Pick's disease, semantic dementia, senile dementia, and vascular dementia.
77 . The use according to claim 75 , wherein the learning disorder is selected from the group consisting of Asperger's syndrome, attention deficit disorder,
attention deficit hyperactivity disorder, autism, childhood disintegrative disorder, and Rett syndrome.
78 . The use according to claim 75 , wherein the aphasia is progressive non-fluent aphasia.
79 . The use according to any of the preceding claims, wherein the cognitive disorder is associated with neurodegenerative disease, injury to the brain, psychiatric disorders, or chronic pain.
80 . The use according to claim 79 , wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, corticobasal degeneration, Creutzfeldt-Jacob disease, frontotemporal lobar degeneration, Huntington disease, multiple sclerosis, normal pressure hydrocephalus, organic chronic brain syndrome, Parkinson's disease, Pick disease, progressive supranuclear palsy, and senile dementia (Alzheimer type).
81 . The use according to claim 79 , wherein the injury to the brain is selected from the group consisting of chronic subdural hematoma, concussion, intracerebral hemorrhage, encephalitis, meningitis, septicemia, drug intoxication, and drug abuse.
82 . The use according to claim 79 , wherein the psychiatric disorders are selected from the group consisting of anxiety disorders, dissociative disorders, mood disorders, schizophrenia, and somatoform and factitious disorders.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.